New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:40 EDTGTXIGTx to present GTx-758 Phase 2 clinical trial preliminary findings
GTx announced that it will present preliminary findings from the company’s Phase 2 clinical trial evaluating GTx-758. The Phase 2 clinical trial is sequentially testing for safety and effectiveness of 125mg oral daily dose and 250mg oral daily dose of GTx-758 as secondary hormonal therapy in men with CRPC. The goal of the Phase 2 trial is to show that lower doses of GTx-758 are well tolerated and effective in reducing free testosterone and, in greater than 50% of subjects, achieving a 50% reduction of serum prostate specific antigen by Day 90. Preliminary data shows that a majority of subjects who were experiencing hot flashes prior to taking GTx-758 have reported improvement in and/or stabilization of their hot flashes and bone turnover biomarkers have decreased in a majority of the patients. As for safety, GTx-758 continues to be well tolerated, with no reported venous thromboembolic events or deaths.
News For GTXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:12 EDTGTXIGTx files to sell 64.31M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use